WO2001000231A3 - Use of cpg as an adjuvant for malaria vaccine - Google Patents
Use of cpg as an adjuvant for malaria vaccine Download PDFInfo
- Publication number
- WO2001000231A3 WO2001000231A3 PCT/EP2000/005841 EP0005841W WO0100231A3 WO 2001000231 A3 WO2001000231 A3 WO 2001000231A3 EP 0005841 W EP0005841 W EP 0005841W WO 0100231 A3 WO0100231 A3 WO 0100231A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cpg
- adjuvant
- malaria vaccine
- vaccine
- administration
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title 1
- 229940124735 malaria vaccine Drugs 0.000 title 1
- 201000004792 malaria Diseases 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 241000223960 Plasmodium falciparum Species 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002376926A CA2376926A1 (en) | 1999-06-29 | 2000-06-23 | Use of cpg as an adjuvant for malaria vaccine |
AU59777/00A AU5977700A (en) | 1999-06-29 | 2000-06-23 | Vaccines |
EP00945810A EP1198243A2 (en) | 1999-06-29 | 2000-06-23 | Use of cpg as an adjuvant for malaria vaccine |
HK02107137.7A HK1047034A1 (en) | 1999-06-29 | 2002-09-26 | Use of cpg as an adjuvant for malaria vaccine |
US11/934,814 US20080131464A1 (en) | 1999-06-29 | 2007-11-05 | Vaccines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9915204.3 | 1999-06-29 | ||
GBGB9915204.3A GB9915204D0 (en) | 1999-06-29 | 1999-06-29 | Vaccine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/789,758 Continuation US20050002958A1 (en) | 1999-06-29 | 2004-02-27 | Vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001000231A2 WO2001000231A2 (en) | 2001-01-04 |
WO2001000231A3 true WO2001000231A3 (en) | 2001-07-05 |
Family
ID=10856286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/005841 WO2001000231A2 (en) | 1999-06-29 | 2000-06-23 | Use of cpg as an adjuvant for malaria vaccine |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1198243A2 (en) |
AU (1) | AU5977700A (en) |
CA (1) | CA2376926A1 (en) |
GB (1) | GB9915204D0 (en) |
HK (1) | HK1047034A1 (en) |
WO (1) | WO2001000231A2 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP1733735B1 (en) | 1998-05-22 | 2017-03-22 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7306806B2 (en) | 2001-01-26 | 2007-12-11 | United States Of America As Represented By The Secretary Of The Army | Recombinant P. falciparum merozoite protein-142 vaccine |
EP1409533A2 (en) * | 2001-01-26 | 2004-04-21 | Walter Reed Army Institute of Research | Recombinant plasmodium falciparum merozoite protein-1/42 vaccine |
JP2005510462A (en) * | 2001-08-10 | 2005-04-21 | ダイナバックス テクノロジーズ コーポレイション | Production of immunomodulating oligonucleotides and methods of use thereof |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20070104726A1 (en) * | 2002-08-14 | 2007-05-10 | Avidis Sa | Multimeric complexes of antigens and adjuvants |
JP4199988B2 (en) * | 2002-11-14 | 2008-12-24 | 大日本印刷株式会社 | Decorative sheet |
EP2066344B2 (en) | 2006-09-07 | 2016-06-29 | GlaxoSmithKline Biologicals S.A. | Inactivated Poliovirus combination vaccine |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002555A1 (en) * | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
WO1998005355A1 (en) * | 1996-08-02 | 1998-02-12 | Smithkline Beecham Biologicals S.A. | Vaccine composition against malaria |
WO1998037919A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
WO1998040100A1 (en) * | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
WO1999011241A1 (en) * | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
WO2000023105A2 (en) * | 1998-10-16 | 2000-04-27 | Smithkline Beecham Biologicals S.A. | Adjuvant systems and vaccines |
WO2000062800A2 (en) * | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010152A1 (en) * | 1991-11-16 | 1993-05-27 | Smithkline Beecham Biologicals S.A. | HYBRID PROTEIN BETWEEN CS FROM PLASMODIUM AND HBsAG |
-
1999
- 1999-06-29 GB GBGB9915204.3A patent/GB9915204D0/en not_active Ceased
-
2000
- 2000-06-23 EP EP00945810A patent/EP1198243A2/en not_active Ceased
- 2000-06-23 CA CA002376926A patent/CA2376926A1/en not_active Abandoned
- 2000-06-23 WO PCT/EP2000/005841 patent/WO2001000231A2/en active Application Filing
- 2000-06-23 AU AU59777/00A patent/AU5977700A/en not_active Abandoned
-
2002
- 2002-09-26 HK HK02107137.7A patent/HK1047034A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996002555A1 (en) * | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
WO1998005355A1 (en) * | 1996-08-02 | 1998-02-12 | Smithkline Beecham Biologicals S.A. | Vaccine composition against malaria |
WO1998037919A1 (en) * | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
WO1998040100A1 (en) * | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
WO1999011241A1 (en) * | 1997-09-05 | 1999-03-11 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
WO2000023105A2 (en) * | 1998-10-16 | 2000-04-27 | Smithkline Beecham Biologicals S.A. | Adjuvant systems and vaccines |
WO2000062800A2 (en) * | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
Non-Patent Citations (1)
Title |
---|
JONES T R ET AL: "Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys", VACCINE,GB,BUTTERWORTH SCIENTIFIC. GUILDFORD, vol. 17, no. 23-24, 6 August 1999 (1999-08-06), pages 3065 - 3071, XP004173617, ISSN: 0264-410X * |
Also Published As
Publication number | Publication date |
---|---|
WO2001000231A2 (en) | 2001-01-04 |
AU5977700A (en) | 2001-01-31 |
CA2376926A1 (en) | 2001-01-04 |
HK1047034A1 (en) | 2003-02-07 |
GB9915204D0 (en) | 1999-09-01 |
EP1198243A2 (en) | 2002-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001000232A3 (en) | Use of cpg as an adjuvant for hiv vaccine | |
AU784403B2 (en) | Pharmaceutical composition for immunomodulation and preparation of vaccines comprising an antigen and an immunogenic oligodeoxynucleotide and a polycationic polymer as adjuvants | |
WO2002028422A3 (en) | Split enveloped virus preparation for intranasal delivery | |
WO2002028428A3 (en) | Vaccine composition | |
WO2002034205A3 (en) | Using heat shock proteins to increase immune response | |
PL351893A1 (en) | Vaccines | |
WO1999033488A3 (en) | Adjuvanted vaccine formulation | |
UA93508C2 (en) | Anti-malaria vaccine | |
WO2001000231A3 (en) | Use of cpg as an adjuvant for malaria vaccine | |
WO2001092470A3 (en) | Dna expression vectors and methods of use | |
WO2000050006A3 (en) | Microemulsions with adsorbed macromoelecules and microparticles | |
LU91326I2 (en) | Human papillomavirus vaccine Ä6,11,16,18Ü (recombinant, adsorbed) | |
WO2003039595A3 (en) | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid | |
WO2001068129A3 (en) | Adjuvant for vaccines | |
WO2002028426A8 (en) | Split enveloped virus preparation | |
AU2001241918A1 (en) | Methods of enhancing activity of vaccines and vaccine compositions | |
AU2151902A (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
AU2002221519A1 (en) | Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens | |
WO2003059385A3 (en) | Hiv vaccine and method of use | |
AU2002343321A8 (en) | Isolation and purification of p. falciparum merozoite protein-142 vaccine | |
WO2001097841A3 (en) | Qs-21 and il-12 as an adjuvant combination | |
WO2003090687A3 (en) | Using heat shock proteins to increase immune response | |
MXPA02010173A (en) | Leishmania. | |
EP0289110A3 (en) | Conjugate malaria vaccine | |
WO2002022687A3 (en) | Viral chemokine-tumur antigen fusion proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000945810 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2376926 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10018704 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000945810 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |